"Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies."

During the past decade, Texas Oncology-Longview Cancer Center conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 36 clinical trials were completed, i.e. on average, 156.5% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 14 clinical trials were completed. i.e. 155.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Oncology-Longview Cancer Center" #1 sponsor was "US Oncology Research" with 10 trials, followed by "Pfizer" with 6 trials sponsored, "Radiation Therapy Oncology Group" with 6 trials sponsored, "National Cancer Institute (NCI)" with 5 trials sponsored and "Celgene" with 5 trials sponsored. Other sponsors include 30 different institutions and companies that sponsored additional 31 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Oncology-Longview Cancer Center" #1 collaborator was "NRG Oncology" with 11 trials as a collaborator, "National Cancer Institute (NCI)" with 9 trials as a collaborator, "Bristol-Myers Squibb" with 4 trials as a collaborator, "Sanofi" with 3 trials as a collaborator and "Astellas Pharma Inc" with 2 trials as a collaborator. Other collaborators include 22 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "Texas Oncology-Longview Cancer Center" are "Breast Cancer" (9 trials), "Prostate Cancer" (8 trials), "Metastatic Breast Cancer" (7 trials), "Lung Cancer" (3 trials) and "Non-Small Cell Lung Cancer" (3 trials). Many other conditions were trialed in "Texas Oncology-Longview Cancer Center" in a lesser frequency.

Most popular intervention types in "Texas Oncology-Longview Cancer Center" are "Drug" (53 trials), "Other" (11 trials), "Radiation" (11 trials), "Biological" (7 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (8 trials), "Laboratory Biomarker Analysis" (8 trials), "Paclitaxel" (8 trials), "Placebo" (8 trials) and "Prednisone" (5 trials). Other intervention names were less common.

The vast majority of trials in "Texas Oncology-Longview Cancer Center" are 42 trials for "All" genders, 13 trials for "Female" genders and 10 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Oncology-Longview Cancer Center". undefined are not yet recruiting, 7 are recruiting, 16 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 37 completed trials in Texas Oncology-Longview Cancer Center, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Oncology-Longview Cancer Center, 3 "Phase 1" clinical trials were conducted, 24 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".